Simplex Trading
DNLI icon

Simplex Trading’s Denali Therapeutics DNLI Stock Holding History

Simplex Trading’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,700
Closed -$854K – 9296
2025
Q4 		$854K Buy
51,700
+48,300
+1,421% +$815K ﹤0.01% 2787
2025
Q3 		$49K Sell
3,400
-3,100
-48% -$44.5K ﹤0.01% 6475
2025
Q2 		$90K Buy
6,500
+5,000
+333% +$70.4K ﹤0.01% 5341
2025
Q1 		$20K Sell
1,500
-700
-32% -$13.4K ﹤0.01% 6573
2024
Q4 		$44K Sell
2,200
-5,100
-70% -$131K ﹤0.01% 6001
2024
Q3 		$212K Buy
7,300
+6,900
+1,725% +$171K ﹤0.01% 4462
2024
Q2 		$9K Sell
400
-28,000
-99% -$538K ﹤0.01% 7492
2024
Q1 		$582K Buy
28,400
+27,900
+5,580% +$524K ﹤0.01% 3698
2023
Q4 		$10K Sell
500
-800
-62% -$15.8K ﹤0.01% 7410
2023
Q3 		$26K Sell
1,300
-500
-28% -$12.7K ﹤0.01% 6384
2023
Q2 		$53K Sell
1,800
-4,100
-69% -$115K ﹤0.01% 5790
2023
Q1 		$135K Sell
5,900
-5,800
-50% -$160K ﹤0.01% 4803
2022
Q4 		$325K Sell
11,700
-700
-6% -$20.8K ﹤0.01% 3640
2022
Q3 		$380K Buy
12,400
+5,700
+85% +$185K ﹤0.01% 3794
2022
Q2 		$197K Buy
6,700
+5,700
+570% +$149K ﹤0.01% 4617
2022
Q1 		$32K Buy
1,000
+700
+233% +$24.1K ﹤0.01% 7693
2021
Q4 		$13K Sell
300
-100
-25% -$4.74K ﹤0.01% 8797
2021
Q3 		$31K Hold
400
– – ﹤0.01% 8058
2021
Q2 		$31K Buy
400
+356
+809% +$22K ﹤0.01% 8195
2021
Q1 		$251K Buy
+44
New +$2.94K ﹤0.01% 4393
2020
Q2 		– Sell
-43
Closed -$75K – 7735
2020
Q1 		$75K Sell
43
-277
-87% -$5.78K ﹤0.01% 4683
2019
Q4 		$557K Buy
320
+305
+2,033% +$5.08K ﹤0.01% 2634
2019
Q3 		$22K Buy
15
+11
+275% +$210 ﹤0.01% 5742
2019
Q2 		$8K Buy
4
+2
+100% +$45 ﹤0.01% 6217
2019
Q1 		$4K Buy
+2
New +$42 ﹤0.01% 6547
2018
Q3 		– Sell
-5
Closed -$7K – 7521
2018
Q2 		$7K Buy
+5
New +$94 ﹤0.01% 6521

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Simplex Trading's DNLI Position: Q1 2026 in Review

Simplex Trading opened a new position in Denali Therapeutics (DNLI) in Q1 2026: 12,315 shares worth $236K. The stake represents ﹤0.01% of the portfolio and ranks #4097 among its holdings. This is a return to the name: Simplex Trading previously reported a position in DNLI as recently as Q3 2025.

Simplex Trading first reported a position in DNLI in Q3 2018 and has held it in 18 quarters since. The position peaked at $418K in Q4 2021. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Simplex Trading held 12,315 shares of Denali Therapeutics worth $236K as of Q1 2026.
  • Denali Therapeutics was a new Simplex Trading position in Q1 2026.
  • Denali Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #4097 holding.
  • Simplex Trading first reported a position in Denali Therapeutics in Q3 2018 and has held it in 18 quarters since.
  • Simplex Trading's Denali Therapeutics position peaked at $418K in Q4 2021.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.